Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Zemplar in birch pollen allergic rhinitis and healthy controls
NL-OMON43601Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of paricalcitol in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Primary immunologic outcome and IL-10 production. Started Nov 2015; status: active, not recruiting.
02
Drugs
paricalcitol
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NL-OMON43601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43601.